Clinical trials: Plaque Psoriasis.
Plaque Psoriasis
LAS41008 in Moderate to Severe Chronic Plaque Psoriasis
The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis
- Trial name
- NCT01726933
- Testing
- LAS41008, LASW1835
- Where
- 4 sites in Austria, Germany and 2 more
- Volunteers
- 839 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
A Physiological Study on Downregulation of EGF-receptors in the Skin by Topical Exposition With EGF
Investigation of EGF-Receptor Downregulation by topical EGF (dermal cream) exposition.
- Trial name
- EGFR (NCT01566578)
- Testing
- Human recombinant epidermal growth factor
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- Ennar Pharmaceuticals AF
Psoriasis Vulgaris
An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A
The purpose of this study is to evaluate the anti-psoriatic effect of injected Botulinum toxin type A compared to that of injected vehicle.
- Trial name
- NCT02577185
- Testing
- Botulinum Toxin Type A, Sodium chloride 9 mg/ml
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- LEO Pharma
Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis
A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks
- Trial name
- NCT07234591
- Testing
- Tyk2 inhibitor
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Usynova Pharmaceuticals Ltd.
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea
- Trial name
- POETYK-PSO-3 (NCT04167462)
- Testing
- BMS-986165
- Where
- 34 sites in China, South Korea and 1 more
- Volunteers
- 220 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
An open label, safety study to assess the potential for adrenal suppression following maximal use treatment with DSXS administered twice daily for 28 days in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT02601469
- Testing
- DSXS
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Plaque Psoriasis Vulgaris
Bioavailability of AZD0284 and IV Microtracer Study
The Sponsor is developing the study drug, AZD0284, for the potential treatment of Plaque psoriasis. Psoriasis is a skin condition that causes red, flaky, crusty patches of skin covered with silvery scales.
- Trial name
- NCT03029741
- Testing
- AZD0284, [14C]AZD0284
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Plaque Psoriasis
Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis
A study to evaluate the safety and efficacy of adalimumab in Chinese subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01646073
- Testing
- Adalimumab
- Where
- 16 sites in China
- Volunteers
- 425 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10
This is a multicenter study of subjects with mild to moderate psoriasis. Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on…
- Trial name
- NCT02322086
- Testing
- Topical Rose Bengal, 0.005%
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Provectus Pharmaceuticals
Psoriasis Vulgaris
A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis
The purpose of this trial is to compare the anti-psoriatic effect of eight different formulations of vitamin D analogues using a psoriasis plaque test design
- Trial name
- NCT01105286
- Testing
- Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Psoriasis Vulgaris
A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products
The purpose of this trial is to evaluate the anti-psoriatic effect of LEO 29102 cream and its combination with calcipotriol and betamethasone using a psoriasis plaque test method.
- Trial name
- NCT00875277
- Testing
- LEO 29102 cream, LEO 29102 Cream Vehicle, Betamethasone Dipropionate Cream
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis
The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of…
- Conditions
- Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
- Trial name
- CIMcare (NCT04123795)
- Testing
- Certolizumab pegol
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 49 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis
The purpose of the study is to determine the safety and efficacy of AN2728 Ointment, 5%, compared to Ointment Vehicle in the treatment of plaque type psoriasis.
- Trial name
- NCT00759161
- Testing
- AN2728, AN2728 Ointment Vehicle
- Where
- Mexico
- Volunteers
- 35 people
- Sponsor
- Pfizer
Moderate to Severe Plaque Psoriasis
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea
The primary objective of this study is to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis randomized in a double-blind manner to receive KHK4827 or placebo for 12 weeks
- Trial name
- NCT02982005
- Testing
- KHK4827
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Kyowa Kirin Korea Co., Ltd.
Chronic Small Plaque Psoriasis
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
The primary objective of the study is to evaluate the safety and tolerability of 50, 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with plaque psoriasis
- Trial name
- NCT00396422
- Testing
- RWJ-445380
- Volunteers
- 60 people
- Sponsor
- Alza Corporation, DE, USA
Psoriasis
Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis
This Phase II study was designed as a multicenter, randomized, double-blind, placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and tolerability of GN-037 versus clobetasol 17-propionate and placebo in…
- Trial name
- NCT05706870
- Testing
- GN-037, Clobetasol 17-propionate
- Where
- 18 sites in Turkey (Türkiye)
- Volunteers
- 190 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.
Plaque Psoriasis
A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation
The main purpose of the study is to determine if PF-06700841 is safe and well tolerated when administered to humans. A secondary purpose is to assess what the body does to PF-06700841 and to assess what PF-06700841 does to the…
- Trial name
- NCT02310750
- Testing
- PF-06700841 oral solution/suspension, PF-06700841 tablet
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- CHAMPION (NCT00235820)
- Testing
- adalimumab, MTX
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Abbott
Plaque Psoriasis
Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis
To compare the safety and efficacy of Padagis' product to an FDA approved product for the treatment of plaque psoriasis
- Trial name
- NCT05763082
- Testing
- roflumilast cream 0.3%, Zoryve
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Padagis LLC
Psoriasis
BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
- Trial name
- NCT02684370
- Testing
- risankizumab, ustekinumab
- Volunteers
- 560 people
- Sponsor
- AbbVie